Brief: Sellas Life Sciences Reaches Target Enrollment Ex-China In Phase 3 Regal Trial Of Galinpepimut-S In Acute Myeloid Leukemia
29/11/2023 16:00
Sellas Life Sciences Group Inc SLS.O :
* SELLAS LIFE SCIENCES REACHES TARGET ENROLLMENT EX-CHINA IN
PHASE
3 REGAL TRIAL OF GALINPEPIMUT-S IN ACUTE MYELOID LEUKEMIA
* SELLAS LIFE SCIENCES GROUP INC - INTERIM ANALYSIS
EXPECTED TO
OCCUR IN LATE 2023 OR EARLY 2024 AND FINAL ANALYSIS ON TRACK TO
OCCUR BY END OF 2024
Source text for Eikon: ID:nGNX3prMP4
Further company coverage: SLS.O
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses